Portions herein identified by [***] have been omitted pursuant to a request for confidential treatment under Rule
406 of the Securities Act of 1933, as amended. A complete copy of this document has been filed separately with
the Securities and Exchange Commission.
RESEARCH AND LICENSE AGREEMENT
This Agreement is entered into as of October 10, 2006 (“Effective Date”), by and between
Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation
organized and existing under the laws of the State of New York, having an office and place of business at 1300
Morris Park Avenue, Bronx, New York 10461 (“AECOM”) and Hana Biosciences, Inc., a corporation
organized and existing under the laws of the State of Delaware, having an office and place of business at 7000
Shoreline Court, Suite 370, South San Francisco, CA 94080 (“Licensee”).
AECOM has established a laboratory directed by Dr. Roman Perez-Soler (“the Investigator”) to
conduct research relating, in part, to the use of Vitamin K for prevention and treatment of skin rash secondary to
anti-EGFR therapy. Licensee wishes to provide financial support for a research project to be conducted by
AECOM in the Investigator’s laboratory and wishes to acquire an exclusive license in the Field (as defined
below) from AECOM with respect to certain patent rights resulting from such research and certain other patent
rights of AECOM, as described herein.
NOW, THEREFORE, in consideration of the promises and mutual covenants, conditions and
limitations herein contained and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, AECOM and Licensee agree as follows:
1.01 “Field” means any and all uses of the Agreement Patents.
1.02 “Agreement Patents” means (1) the provisional and international patent applications listed on
Appendix A, together with any and all patents which issue from